Asthalin (salbutamol sulfate) is a selective short-acting β2-adrenergic receptor agonist (SABA) indicated for the treatment and prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD). As a first-line rescue medication, it works by relaxing the smooth muscles of the airways, leading to rapid bronchodilation, improved airflow, and relief from acute respiratory symptoms. Its formulation is designed for quick onset, making it an essential component in both personal and clinical management plans for respiratory distress.

Features

• Contains salbutamol sulfate as the active pharmaceutical ingredient (API)
• Available in multiple delivery forms: pressurized metered-dose inhaler (pMDI), dry powder inhaler (DPI), nebulizer solution, and syrup
• Rapid onset of action, typically within 5–15 minutes of inhalation
• Duration of effect lasts approximately 4–6 hours
• Portable and user-friendly device designs for emergency use
• Precisely metered doses ensuring consistent delivery

Benefits

• Provides rapid relief from acute episodes of wheezing, shortness of breath, and chest tightness
• Helps restore normal breathing patterns and improve exercise tolerance in asthmatic patients
• Reduces the frequency and severity of asthma attacks when used as prescribed
• Supports management of bronchospasm associated with COPD
• Enables quick intervention during exacerbations, potentially reducing emergency room visits
• Available in various formulations to suit different age groups and patient preferences

Common use

Asthalin is commonly prescribed for the management of bronchospasm in conditions such as asthma, exercise-induced bronchoconstriction (EIB), and chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. It is also used prophylactically to prevent bronchospasm triggered by allergens, exercise, or environmental factors. In clinical settings, it may be administered via nebulization for patients experiencing severe respiratory distress.

Dosage and direction

Dosage must be individualized based on patient need, severity of condition, and delivery device. For inhalation via pMDI (100 mcg/puff): adults and children over 4 years—1–2 puffs every 4–6 hours as needed. Maximum 8 puffs in 24 hours. For nebulization: 2.5 mg to 5 mg up to 4 times daily. Oral syrup: adults—2–4 mg (4–8 ml) 3–4 times daily; children—0.1 mg/kg/dose 3 times daily (not to exceed 2 mg 3–4 times daily). Shake the inhaler well before use. Prime the inhaler if new or unused for 2 weeks. Administer during slow, deep inhalation; hold breath for 10 seconds if possible. Rinse mouth after use to reduce systemic absorption and potential side effects.

Precautions

Use with caution in patients with cardiovascular disorders (e.g., hypertension, arrhythmias, coronary insufficiency), diabetes mellitus, hyperthyroidism, or convulsive disorders. Monitor for paradoxical bronchospasm—discontinue immediately if it occurs. Excessive use may lead to tolerance and loss of effectiveness; increased use may indicate deteriorating asthma control. Not intended for regular daily use unless specifically directed. Pregnancy Category C: use only if potential benefit justifies potential risk to the fetus. Elderly patients may be more susceptible to adverse effects.

Contraindications

Hypersensitivity to salbutamol sulfate or any component of the formulation. Contraindicated in patients with tachyarrhythmias and known hypersensitivity to sympathomimetic amines.

Possible side effects

Common side effects include tremor, nervousness, headache, tachycardia, palpitations, muscle cramps, and dry or irritated throat. Less frequently, patients may experience hypokalemia, increased blood pressure, dizziness, nausea, and sweating. Paradoxical bronchospasm, angina, and sleep disturbances have been reported rarely. Allergic reactions such as rash, urticaria, and oropharyngeal edema are possible.

Drug interaction

Concomitant use with other sympathomimetic agents may potentiate cardiovascular effects. Use with monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants may enhance cardiovascular effects. Beta-blockers (non-selective) may antagonize bronchodilating effects and induce severe bronchospasm in asthmatic patients. Diuretics or corticosteroids may enhance hypokalemic effect. Use cautiously with xanthine derivatives, steroids, or diuretics.

Missed dose

Asthalin is typically used on an as-needed basis for symptom relief. If using a scheduled dosing regimen and a dose is missed, administer it as soon as remembered unless it is nearly time for the next dose. Do not double the dose.

Overdose

Overdose may lead to exaggerated adrenergic effects such as angina, hypertension, hypokalemia, seizures, tachycardia, and cardiac arrest. Symptoms may also include nausea, vomiting, and metabolic acidosis. Treatment is supportive and symptomatic; cardioselective beta-blockers may be considered but with caution due to risk of bronchospasm.

Storage

Store at controlled room temperature (15–30°C). Keep the canister away from direct heat or sunlight. Do not puncture, incinerate, or expose to temperatures above 50°C. Keep out of reach of children. For nebulizer solution: store in foil pouch until use; protect from light.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and before starting or changing any medication regimen.

Reviews

“Asthalin has been a lifesaver during my asthma attacks. Works within minutes.” – Priya M., asthma patient
“Effective and reliable bronchodilator. Essential in our emergency protocol.” – Dr. Alan Richter, pulmonologist
“Easy to use inhaler. My go-to rescue medication for years.” – Michael T.
“Quick relief for my son’s exercise-induced symptoms. Highly recommend.” – Sarah L.